Clinical Experience of Using Paroxetine While Treating Elderly Depressed Patients
https://doi.org/10.30629/2618-6667-2019-17-4-6-14
Abstract
Objective: study of Paroxetine clinical impact while treating elderly depressed in-patients of Mental health research centre.
Patients and methods: study concerned in-patients older than 50 years with depression in accordance to depressive episode defined by ICD-10. The severity of depression according to Hamilton depression scale (HAMD-17) was at least 14 points. The study was open, non-comparative, and lasted for 28 days. The clinical psychopathological and psychometrical methods with standard scales (HAMD, HAMA, CGI) were used. The study concerned 40 patients aged from 50 to 77 years old (middle age — 62 y.o.). The severity of depression before therapy according to HAMD scale was 19,6 points, the anxiety extent according to HAMA was 15 points.
Results: 31(77,5%) patients completed the study. 6 patients (15,0%) stopped the study because of ineffectiveness, and 3 patients withdrawn because of adverse events (7,5%). The therapy efficiency was 63,3% according to HAMD scale at the end of the treatment and 63,5% according to HAMA. The number of responders according to HAMD was 78,4%. Reduction of anxious and depressive symptoms was observed by the end of first week of therapy. The effectiveness of therapy decreased in case of cognitive and hypochondriac disorders. Cognitive indicants improvement and high tolerability were observed. Some light gastrointestinal symptoms were stated as adverse events.
Conclusion: paroxetine is an effective antidepressant medication for anxious depressions treatment in elderly.
About the Authors
V. S. Sheshenin
FSBSI Mental Health Research Centre
Russian Federation
Russian Federation
VladimirS. Sheshenin - PhD, MD, Cand. of Sci. (Med.).
Moscow
V. V. Ryakhovsky
FSBSI Mental Health Research Centre
Russian Federation
Russian Federation
Vyacheslav V. Ryakhovskiy - PhD, MD, Cand. of Sci. (Med.), Senior Researcher.
MoscowReferences
1. Sartorius N. Depression: The global aspects of the problem. WPA Bulletin on Depression. 2003;6(25):3-4.
2. Gavrilova SI., Kalyn YAB. Sotsial'no-sredovye faktory i sostoyanie psikhiche-skogo zdorov'ya pozhilogo naseleniya (kliniko-ehpidemiologicheskoe issledo-vanie). Vestnik RАMN. 2002;9:15-20. (In Russ.).
3. Baldwin R, Wild R. Management of depression in later life. Advances in Psychiatric Treatment. 2004;10:131-139. https://D0I.org/10.1192/apt.10.2.131.
4. Blazer D. Depression in Late Life: Review and Commentary. The Journals of Gerontology: Series A. 2003;58(3):M249-M265. https://D0I.org/10.1093/gerona/58.3.M249.
5. Comfort A. Depression in the elderly. The Lancet. 1986;328(8502):338. https://D0I.org/10.1016/S0140-6736(86)90023-1.
6. Safarova TP, Gavrilova SI, Yakovleva OB, et al. Augmentatsiya karnitsetinom terapii pozdnikh depressij. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(5):65-75. (In Russ.). https://DOI.org/10.17116/jnevro201911905165.
7. Kontsevoj VA, Andrusenko MP. Voprosy terapii de-pressij v pozdnem vozraste. Kremlevskaya meditsina. 2001;3:66-73. (In Russ.).
8. Kruglov LS, Meshandin !А. Pozdnevozrastnaya depressiya u bol'nykh s tserebral'no-sosudistymi narusheniyami: osobennosti klinicheskoj kartiny i terapevticheskoj dinamiki. Obozrenie psikhiat-rii i meditsinskoj psikhologii imeni V.M. Bekhtereva. 2011;1:22-25. (In Russ.).
9. Kontsevoj VA, Yakovleva OB, Safarova TP, Sheshe-nin VS. Ispol'zovanie tsipramila pri lechenii depressij v starosti. Zhurn. psikhiatriya ipsikhofarmakoterapiya. 2003;2:68-71. (In Russ.).
10. Taylor W. Clinical practice: depression in the elderly. N. Engl. J. Med. 2014;371(13):1228-1236. https://D0I.org/10.1056/NEJMcp1402180.
11. Bali V, Chatterjee S, Johnson ML, et al. Risk of Mortality in Elderly Nursing Home Patients with Depression Using Paroxetine. Pharmacotherapy. 2017;37(3):287-296. https://D0I.org/10.1002/phar.1898.
12. Tyuvina NA, Prokhorova SV, Maksimova TN. EHffek-tivnost' paksila pri lechenii depressij u muzhchin pozhilogo vozrasta. Nevrologiya, nejropsikhiatriya, psikhosomatika. 2012;2:63-68. (In Russ.).
13. Bourin M, Chue P, Guillon Y. Paroxetine: a review. CNS Drug Rev. 2001.Spring;7(1):25-47. https://dx.DOI.org/10.1111%2Fj.1527-3458.2001.tb00189.x.
14. Retyunskij KYu, Khmel'nova IV, Mal'kova EB. Terapevticheskaya ehffektivnost' reksetina pri sosudistoj depressii. Psikhiatriya i psikhofarmakoterapiya. 2005;7(6):346-349. (In Russ.).
15. Mosolov SN, Smulevich AB, Grigor'evskikh VS, et al. Klinicheskaya ehffektivnost' i perenosimost' preparata «Paksil» (paroksetin) pri lechenii depressii. Psikhiatriya i psikhofarmakoterapiya. 2004;4:164-168. (In Russ.).
16. Drobizhev MYu, Syrkin AL, Ivanov SV, Pecherskaya MB. Paroksetin pri lechenii depressij u bol'nykh obshhe-somaticheskogo statsionara. Рsikhiatriya ipsikhofarmakoterapiya. 2000;2(4):5-9. (In Russ.).
17. Anstey K, Brodaty H. Antidepressants and the elderly: Double-blind trials 1987-1992. International Journal of Geriatric Psychiatry. 1995;10(4):265-279. https://D0I.org/10.1002/gps.930100403.
18. Bobrov AS, Petrun'ko OV, Kovaleva AV et al. Reksetin v terapii depressivnykh sostoyanij. Zhurnal nevrologii i psihiatrii imeni S.S. Korsakova. 2005;105(11):30-34. (In Russ.).
19. Cole M, Elie L, McCusker J, et al. Feasibility and effectiveness of treatments for depression in elderly medical inpatients: a systematic review. Int Psychogeri-atr. 2000;12(4):453-461. https://DOI.org/10.1017/S1041610200006578.
20. Rumyantseva GM, Stepanov AL, Levina TT. Klinicheskaya ehffektivnost' preparata «Reksetin» (parok-setin) pri rasstrojstvakh trevozhnogo spektra. Psikhiatriya i psikhofarmakoterapiya. 2005;7(5):292-294. (In Russ.).
21. Kruglov LS, Meshandin IA. Pozdnevozrastnaya depressiya u bol'nykh s tserebral'no-sosudistymi narusheniyami. Osobennosti klinicheskoy kartiny i terapevticheskoy dinamiki. Obozreniye psikhiatriiт i meditsinskoy psikhologii imeni V.M. Bekhtereva. 2011;(1):22-25. (In Russ.).
Review
For citations:
Sheshenin V.S., Ryakhovsky V.V. Clinical Experience of Using Paroxetine While Treating Elderly Depressed Patients. Psychiatry (Moscow) (Psikhiatriya). 2019;17(4):6-14. (In Russ.) https://doi.org/10.30629/2618-6667-2019-17-4-6-14
Views:
1471
Email this article 
